Sutro bio stock
WebThe Sutro Biopharma stock forecast for tomorrow is $ 4.77, which would represent a -0.09% loss compared to the current price. In the next week, the price of STRO is … WebDescription. Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis ...
Sutro bio stock
Did you know?
Web8 apr 2024 · PDL BioPharma, Inc. (NASDAQ:PDLI) released its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.10 by $0.53. The biotechnology company earned $5.21 million during the quarter. Web17 feb 2024 · Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference. Jan 4, 2024. SOUTH SAN FRANCISCO, Calif., January 4, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), …
WebEnvío gratis. Tiempos de entrega 48/72 horas. Productos nuevos 100% originales y de primeras marcas. Pago seguro SSL. Devoluciones y Garantía.
Web10 apr 2024 · 6 equities research analysts have issued 1-year target prices for Sutro Biopharma's shares. Their STRO share price forecasts range from $8.00 to $25.00. On … Web27 mar 2024 · Sutro Biopharma, Inc. Common Stock (STRO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Web6 apr 2024 · A high-level overview of Sutro Biopharma, Inc. (STRO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Web6 apr 2024 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Sutro Biopharma stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for STRO. The average twelve-month price prediction for Sutro Biopharma is $17.83 with a high price target of $25.00 and a low price target of $8.00. new delorean dmc-12WebStock Data; SEC Filings; Governance; Pipeline; News. News Releases; Clinical / Scientific Presentation & Publication Highlights; Events; Events Audio Replays; ... Sutro Biopharma. 111 Oyster Point Blvd South San Francisco, CA 94080 Phone: 650-881-6500 Fax: 650-553-9659. Google Map. Tweets by @sutrobio. new delta kitchen faucet low pressureWeb1 mar 2024 · Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned … internorm hs330WebSUTRO BIOPHARMA, INC. : Financial analyst guidance for SUTRO BIOPHARMA, INC. Stock Nasdaq: STRO Nasdaq internorm international gmbhWeb30 mar 2024 · As of December 31, 2024, Sutro had cash, cash equivalents and marketable securities of $302.3 million, as compared to $287.3 million as of September 30, 2024, and approximately 0.7 million shares of Vaxcyte common stock with a fair value of $32.0 million, which together provide a projected cash runway into the second half of 2024, based on … new del webb communitiesWeb15 mar 2024 · View the latest Sutro Biopharma Inc. (STRO) stock price, news, historical charts, analyst ratings and financial information from WSJ. internorm jobs traunWeb10 apr 2024 · 6 equities research analysts have issued 1-year target prices for Sutro Biopharma's shares. Their STRO share price forecasts range from $8.00 to $25.00. On average, they predict the company's share price to reach $17.33 in the next twelve months. This suggests a possible upside of 301.2% from the stock's current price. new del webb locations